Pulmonary Hypertension Treatments: Letairis (Ambrisentan)

Author: Shelley Ensz. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer

Letairis® (Ambrisentan) by Gilead

"PAH is high blood pressure in the arteries of the lungs. Letairis can improve your ability to exercise, and it can help slow down the worsening of your physical condition and symptoms." Gilead

Letairis abstract watercolorLetairis® (Ambrisentan) was approved by the US FDA for the treatment of pulmonary artertial hypertension (PAH) in June 2007, for people with WHO class II or III symptoms. It relaxes blood vessels and improves circulation, thus improving exercise capacity and delaying worsening. It is a pill which is taken once a day. Usually people are started at 5mg and if that is well tolerated, it is increased to 10mg. (Also see Pulmonary Involvement, Pulmonary Hypertension, and PH/PAH Treatments)

Letairis Support. Patient assistance program and pharmacy access. Unlike many other medicines, Letairis is not available at your local retail pharmacy. Instead, Letairis will be mailed directly to your home. Gilead.

Letairis (ambrisentan) Prescribing Information. Letairis safety, side effects, and prescribing information. Gilead.

Letairis (ambrisentan) is a potent type-A selective endothelin receptor antagonist. Endothelin is a peptide made by the body in the endothelium. It constricts blood vessels and elevates blood pressure. Endothelin receptor antagonists (ETRAs) are a class of drugs which prevent the constriction or narrowing of blood vessels thereby enhancing blood flow throughout the body. CenterWatch.

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure (mPAP) associated with systemic sclerosis. This is the first randomized, double-blind, placebo-controlled study testing the effect of ambrisentan in patients with mildly elevated mPAP and/or exercise pulmonary hypertension. PubMed, Arthritis Res Ther, 2019 Oct 26;21(1):217. (Also see Endothelin Receptor Antagonists and Clinical Trials)

Combination of Letairis® with ADCIRCA®

The combination of Letairis and Tadalafil reduced risk of progression by 50 percent in PAH WHO Group 1, compared to either therapy alone.

Tadalafil (ADCIRCA®) is FDA approved for the treatment of pulmonary arterial hypertension (PAH). It is a pill that is taken once a day, and can improve exercise ability in PAH. It is manufactured by Eli Lilly and Company, and marketed by Lung Biotechnology PBC, which is a wholy-owned subsidiary of United Therapeutics Corporation. Lung Biotechnology PBC.

Go to Macitentan (Opsumit)

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.